Kangji Medical sees revenue rise, profit dip in interim results

Kangji Medical Holdings Limited reported revenue of RMB496.6 million for the six months ended June 30, 2025, an 8.3% increase compared to RMB458.4 million in the corresponding period of 2024. This growth was primarily attributed to increased sales of disposable products. Disposable products accounted for 90.9% of total revenue. However, net profit attributable to owners decreased by 7.0%, from RMB285.8 million in 2024 to RMB265.8 million in 2025, mainly due to a decrease in other income and gains and an increased share of loss in Weijing Medical.

Gross profit for the period increased by 8.1% to RMB392.4 million, maintaining a stable gross profit margin of 79.0%. Selling and distribution expenses decreased by 3.0% to RMB37.9 million, while administrative expenses saw a significant 25.9% reduction to RMB37.7 million. Research and development expenses were RMB33.9 million, down 21.9% from the previous year.

The company's total capital expenditure for the period was approximately RMB17.2 million, primarily for machinery and building construction. As of June 30, 2025, Kangji Medical had net current assets of RMB1,834.8 million and cash and cash equivalents of RMB1,707.2 million. The board did not recommend an interim dividend for the six months ended June 30, 2025.